At its September meeting, the EMA’s CHMP recommended three innovative medicines for EU market approval.

Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and  metabolism of the malaria parasite Plasmodium falciparum.

Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.

Danish Lundbeck AS is has secured a stake in the  migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc. 

Prague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.

The Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.

German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.

French biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.

Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
 

Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.